Avalo Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Avalo Therapeutics

12/08/2024 15:30

* Avalo Therapeutics Inc  AVTX.OQ  reported a quarterly
adjusted
loss of $14.07​​ per share for the quarter ended in June, higher
than the same quarter last year, when the company reported EPS
of $-141.60.  The lone analyst forecast for the quarter was
for a loss of $6.70 per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Avalo Therapeutics Inc's reported EPS for the quarter was
$4.21​.
    * The company reported quarterly net income of $98.46
million.
    * Avalo Therapeutics Inc shares had fallen by 14.4% this
quarter and gained 17.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 3,426.3% in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Avalo
Therapeutics Inc is $35.00 
This summary was machine generated from LSEG data August 12 at
02:30 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -6.70          -14.07         Missed
 Mar. 31 2024      -1.18          -1.41 hundred  Missed
 Dec. 31 2023      -4.80          -1.16 hundred  Missed
 Sep. 30 2023      -2.64 hundred  -26.40         Beat